Skip to main content

Advertisement

SpringerLink
Log in

Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series

  • Case Report
  • Published:
Clinical Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Three patients aged 79, 75, and 81 years with unresectable hepatocellular carcinoma (HCC) and undergoing maintenance hemodialysis were treated with a combination of atezolizumab and bevacizumab. The patients, respectively, received their 22nd, 2nd, and 4th treatment cycles, and one achieved long-term stable disease. No serious adverse events, including immune-related adverse events, were observed in any patient. Remarkable progress has been made in chemotherapy for cancer; however, the efficacy and safety of chemotherapy in patients undergoing hemodialysis have not been adequately elucidated. This report provides novel insights into the feasibility and outcomes of atezolizumab and bevacizumab combination therapy in patients with HCC undergoing hemodialysis, highlighting its potential as a viable treatment option with manageable side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Abbreviations

HCC:

Hepatocellular carcinoma

CKD:

Chronic kidney disease

CT:

Computed tomography

RECIST:

Response Evaluation Criteria in Solid Tumors

SD:

Stable disease

PD:

Progressive disease

IrAE:

Immune-related adverse events

ESRD:

End‐stage renal disease

BCLC:

Barcelona Clinic Liver Cancer

PIVKA-II:

Protein induced by vitamin K absence or antagonist-II

References

  1. Hiyamuta H, Yamada S, Taniguchi M, et al. Causes of death in patients undergoing maintenance hemodialysis in Japan: 10-year outcomes of the Q-Cohort Study. Clin Exp Nephrol. 2021;25:1121–30.

    Article  PubMed  Google Scholar 

  2. Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383–90.

    Article  PubMed  Google Scholar 

  3. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

    Article  PubMed  Google Scholar 

  4. Panoilia E, Schindler E, Samantas E, et al. A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. Cancer Chemother Pharmacol. 2015;75:791–803.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Klajer E, Garnier L, Goujon M, et al. Targeted and immune therapies among patients with metastatic renal carcinoma undergoing hemodialysis: a systemic review. Semin Oncol. 2020;47:103–16.

    Article  CAS  PubMed  Google Scholar 

  6. Garnier-Viougeat N, Rixe O, Paintaud G, et al. Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant. 2007;22:975.

    Article  PubMed  Google Scholar 

  7. Takayama T, Haga I, Nakamura A, et al. Bevacizumab plus UFT regimen for four patients with stage IV colorectal cancer receiving hemodialysis. Gan To Kagaku Ryoho. 2020;47:1117–9.

    PubMed  Google Scholar 

  8. Watanabe H, Ohira G, Miyauchi H, et al. Long-term control of metastatic colon cancer by chemotherapy in a patient on hemodialysis. Gan To Kagaku Ryoho. 2018;45:2396–8.

    PubMed  Google Scholar 

  9. Aimono Y, Kamoshida T, Okawara A, et al. A case of rectal cancer and multiple liver metastases treated using mFOLFOX and bevacizumab under maintenance dialysis. Gan To Kagaku Ryoho. 2018;45:985–7.

    PubMed  Google Scholar 

  10. van Berlo-van de Laar IRF, Brummelhuis WJ, Imholz ALT, et al. Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. J Clin Pharm Ther. 2018;43:574–7.

    Article  PubMed  Google Scholar 

  11. Takeda T, Miyake M, Tanaka K, et al. XELOX plus Bevacizumab chemotherapy for a patient with postoperative recurrence of colorectal cancer under hemodialysis for chronic renal failure. Gan To Kagaku Ryoho. 2015;42:1594–6.

    PubMed  Google Scholar 

  12. Matsuda M, Seyama Y, Inada K, et al. Third-line therapy in a patient with recurrent colon cancer undergoing hemodialysis. Gan To Kagaku Ryoho. 2013;40:1397–400.

    PubMed  Google Scholar 

  13. Sato Y, Doden K, Nishida Y, et al. Bevacizumab therapy for a colorectal cancer patient or hemodialysis with hepatic metastasis. Gan To Kagaku Ryoho. 2013;40:647–50.

    PubMed  Google Scholar 

  14. Syrios J, Kechagias G, Tsavaris N. Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review. BMC Nephrol. 2013;14:84.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Kuwabara H, Baba H, Wakabayashi M, et al. mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer. Gan To Kagaku Ryoho. 2011;38:2250–2.

    PubMed  Google Scholar 

  16. Horimatsu T, Miyamoto S, Morita S, et al. Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol. 2011;68:263–6.

    Article  CAS  PubMed  Google Scholar 

  17. Lee Y-C, Huang W-T, Lee M-Y, et al. Bevacizumab and Atezolizumab for unresectable hepatocellular carcinoma: real-world data in Taiwan-Tainan Medical Oncology Group H01 Trial. In Vivo. 2023;37:454–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Zhang N, Liu C, Di W. Systemic treatment for gynecological cancer patients undergoing hemodialysis. Onco Targets Ther. 2023;16:545–58.

    Article  ADS  PubMed  PubMed Central  Google Scholar 

  19. Cheun H, Kim M, Lee H, et al. Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. Invest New Drugs. 2019;37:579–83.

    Article  PubMed  Google Scholar 

  20. Wang J, Dasari S, Elantably D, et al. Use of PD-1 inhibitors in patients with end-stage renal disease: safety and clinical outcomes from real-world data. Acta Oncol. 2022;61:1157–61.

    Article  CAS  PubMed  Google Scholar 

  21. Imai R, Kitamura A. Successful treatment with atezolizumab in a haemodialysis patient with large cell neuroendocrine carcinoma. Respirol Case Rep. 2023;11: e01193.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Watari N, Yamaguchi K, Masuda T, et al. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: two case reports. Thorac Cancer. 2021;12:2956–60.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Parisi A, Cortellini A, Cannita K, et al. Safe Administration of anti-PD-L1 Atezolizumab in a patient with metastatic urothelial cell carcinoma and end-stage renal disease on dialysis. Case Rep Oncol Med. 2019;2019:3452762.

    PubMed  PubMed Central  Google Scholar 

  24. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

    Article  CAS  PubMed  Google Scholar 

  25. Oda M, Kisaka Y, Ogawa A, et al. Successful treatment of a patient with hepatocellular carcinoma on hemodialysis using a combination of atezolizumab and bevacizumab: a case report. Kanzo. 2023;64:632–40 (English abstract).

Download references

Acknowledgements

We thank all the members of the Department of Gastroenterology and Gastroenterological Surgery, Shizuoka General Hospital.

Funding

No funding was received for conducting this study.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Shizuoka General Hospital, 4-27-1 Kita Ando, Aoi-Ku, Shizuoka City, Shizuoka, Japan

    Koki Sakaguchi, Tatsunori Satoh, Shinya Kawaguchi, Shinya Endo, Naofumi Shirane & Kazuya Ohno

  2. Department of Gastroenterology, Yaizu City Hospital, Shizuoka, Japan

    Takuya Aoyama

  3. Division of Interventional Radiology, Shizuoka Cancer Center, Shizuoka, Japan

    Kazuhisa Asahara

  4. Department of Gastroenterological Surgery, Shizuoka General Hospital, Shizuoka, Japan

    Hideyuki Kanemoto & Noriyuki Oba

Authors
  1. Koki Sakaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tatsunori Satoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shinya Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takuya Aoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kazuhisa Asahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinya Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Naofumi Shirane
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hideyuki Kanemoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Noriyuki Oba
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kazuya Ohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Koki Sakaguchi and Tatsunori Satoh: manuscript drafting, Tatsunori Satoh: conception and design. All authors reviewed and approved the final version of the manuscript for submission.

Corresponding author

Correspondence to Tatsunori Satoh.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Human and animal rights

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Patient consent

Informed consent was obtained from the patients.

Informed consent

Informed consent was obtained from the patient included in this study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sakaguchi, K., Satoh, T., Kawaguchi, S. et al. Safety and efficacy of atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma undergoing dialysis: a case series. Clin J Gastroenterol (2024). https://doi.org/10.1007/s12328-024-01946-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12328-024-01946-7

Keywords

Search

Navigation